Halozyme: Bristol Myers receives positive CHMP opinion for Opdivo/Enhanze
Halozyme Therapeutics (HALO) announced that Bristol Myers Squibb (BMY) received a positive opinion from the Committee for Medicinal Products ...
Halozyme Joins the $1 Billion Club
Halozyme Therapeutics, Inc. (HALO) shares up after passing $1 billion in revenue for first time, strong guidance.
KLP Kapitalforvaltning AS Invests $1.25 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
KLP Kapitalforvaltning AS acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) in the ...
Thrivent Financial for Lutherans Has $1.87 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Thrivent Financial for Lutherans reduced its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 83.2% in ...
Fierce Pharma5d
Merck lays out subcutaneous Keytruda data in lung cancer amid patent brawl with Halozyme
Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...
Halozyme: Bristol Myers Squibb Secures CHMP's Positive Opinion For New Cancer Drug Delivery Method
Monday announced that Bristol Myers Squibb (BMY) received a positive opinion from the Committee for Medicinal Products for Human Use ...
Investing11d
Halozyme announces CTO retirement, effective immediately
SAN DIEGO, CA – Halozyme Therapeutics , Inc. (NASDAQ:HALO), a biopharmaceutical company with over $1 billion in annual revenue and impressive 22.4% year-over-year growth, announced today that ...
FXEmpire.com11d
Halozyme Joins the $1 Billion Club
The company’s product pipeline and regulatory situation make it primed for growth. Halozyme’s fourth-quarter fiscal 2024 earnings report showed that it passed $1 billion in annual revenue for ...